Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01031563 · ClinicalTrials.gov registry record
Risk Perception in Drug-Dependent Adults With and Without Schizophrenia
A clinical trial of Schizophrenia and Cocaine Dependence, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT01031563: Completed study of Schizophrenia and Cocaine Dependence, sponsored by National Institute on Drug Abuse (NIDA).
NCT01031563 is a study of Schizophrenia and Cocaine Dependence that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 120 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01031563, a study of Schizophrenia and Cocaine Dependence, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: * Several studies of risk perception have demonstrated a common bias known as unrealistic optimism, in which individuals feel they are less likely than other people to experience unpleasant or harmful events in their lives, but more likely to experience pleasant or beneficial events. * Previous research has indicated that individuals with schizophrenia have less of a sense of unrealistic optimism about adverse events than individuals without schizophrenia. However, research on risk perception in schizophrenia is sparse, primarily reporting on behaviors and decisions in the laboratory that likely are influenced by risk perception. * Risk perception among substance users may be viewed in two separate categories: perception of vulnerability to adverse events and perception of vulnerability to negative outcomes associated with substance use. Research in both areas has yielded mixed results. Researchers are interested in studying the connections among schizophrenia, addiction, and risk perception in order to develop better drug use prevention and treatment programs for people with and without schizophrenia. Objectives: \- To compare unrealistic optimism bias in people with and without schizophrenia and/or drug dependence, and its association with actual risky behavior. Eligibility: * Individuals between 18 and 64 years of age who fall into one of the following study categories: * diagnoses of both drug dependence (marijuana or cocaine) and schizophrenia/schizoaffective disorder * diagnosis of drug dependence only (marijuana or cocaine) * diagnosis of schizophrenia/schizoaffective disorder only * healthy volunteers with no history of drug use or serious mental disorder Design: * The study will require a single visit to the research center for a 5- to 6-hour session. * Participants will complete questionnaires on medical and behavioral history, complete tests of thinking skills like memory and attention, complete a brief computerized decision-making task
Conditions Studied
Study Locations (1)
Maryland
- Maryland Psychiatric Research Center (MPRC) 55 Wade Avenue - Catonsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2009-08-18 |
| Est. Completion | 2012-05-03 |
What the finished NCT01031563 record still lists
NCT01031563 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (45% lower).
The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 0 interventions.
NCT01031563 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01031563 about?
NCT01031563 is a clinical study titled "Risk Perception in Drug-Dependent Adults With and Without Schizophrenia". Background: * Several studies of risk perception have demonstrated a common bias known as unrealistic optimism, in which individuals feel they are less likely than other people to experience unpleasant or harmful events in their lives, but more likely to experience pleasant or beneficial events. * ...
What is the current status of trial NCT01031563?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2009-08-18. Estimated completion is 2012-05-03.
What conditions does trial NCT01031563 study?
This clinical trial studies the following conditions: Schizophrenia, Cocaine Dependence, Cannabis Dependence.
Who is sponsoring clinical trial NCT01031563?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01031563 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01031563's enrollment target sits among peer trials
120 120th of 315 higher than 190 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI